MicroPort CardioFlow Medtech Corp. (2160) AI Stock Analysis

• Market Cap: HK$2.68B
• Dividend Yield: N/A
• Average Volume (3M): 8.07M
• Price to Earnings (P/E): 504.5
• Beta (1Y): 1.84
• Revenue Growth: -4.38%
• EPS Growth: N/A
• Country: HK
• Employees: 430
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.10
• Shares Outstanding: 2,412,706,800
• 10 Day Avg. Volume: 7,535,058
• 30 Day Avg. Volume: 8,069,439
• PEG Ratio: 0.34
• Price to Book (P/B): 0.68
• Price to Sales (P/S): 4.13
• P/FCF Ratio: -5.53
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: HK$1.00 ▼(-9.91% Downside)

The overall stock score is primarily impacted by financial performance and technical analysis. While the company has a strong equity base and revenue growth, ongoing losses and cash flow issues are significant concerns. The technical indicators suggest bearish momentum, and the high P/E ratio indicates overvaluation, further weighing down the score.

Positive Factors

Strong Equity Base

A strong equity base provides financial stability and flexibility, allowing the company to invest in growth opportunities and withstand economic fluctuations.

Revenue Growth

Consistent revenue growth indicates successful market penetration and product acceptance, supporting long-term business expansion and competitive positioning.

Low Leverage

Low leverage reduces financial risk, providing the company with greater resilience against economic downturns and flexibility in financial planning.

Negative Factors

Persistent Losses

Ongoing losses undermine financial health and can limit the company's ability to invest in growth, potentially affecting long-term sustainability and competitiveness.

Negative Cash Flow

Negative cash flow highlights operational inefficiencies, posing risks to liquidity and the ability to fund operations and growth initiatives without external financing.

Profitability Challenges

Profitability challenges can hinder the company's ability to generate sustainable returns, impacting its capacity to reinvest in innovation and competitive strategies.

MicroPort CardioFlow Medtech Corp. Business Overview & Revenue Model

Company Description

MicroPort CardioFlow Medtech Corp. (2160) is a leading medical technology company specializing in the development and manufacturing of innovative cardiovascular devices and solutions. The company operates primarily in the healthcare sector, focusing on products that enhance the treatment and management of heart-related conditions. Its core offerings include advanced cardiac devices, minimally invasive surgical tools, and diagnostic equipment, aimed at improving patient outcomes and supporting healthcare professionals in their daily practices.

How the Company Makes Money

MicroPort CardioFlow Medtech Corp. generates revenue through the sale of its medical devices and technologies to hospitals, clinics, and healthcare providers. The company’s key revenue streams include direct sales of cardiovascular devices, such as stents and balloons, as well as maintenance and support services for its products. Additionally, it may engage in partnerships with healthcare organizations and distributors to expand its market reach and enhance product distribution. Strategic collaborations with research institutions and participation in clinical trials can also contribute to revenue through grants and funding, while ongoing investments in R&D help drive future innovations and sales growth.

MicroPort CardioFlow Medtech Corp. Financial Statement Overview

Summary

MicroPort CardioFlow Medtech Corp. shows strong revenue growth and a solid equity base, but persistent losses and cash flow challenges are significant concerns. The balance sheet strength provides some buffer, but operational efficiencies need improvement for sustainable profitability.

Income Statement

MicroPort CardioFlow Medtech Corp. has shown substantial revenue growth over the years, with a revenue growth rate of 7.54% from 2023 to 2024. However, the company is struggling with profitability as indicated by negative EBIT and net income, resulting in negative EBIT and net profit margins. The gross profit margin improved slightly, showing a focus on cost management, but overall profitability remains a challenge.

Balance Sheet

The company's balance sheet is relatively strong with a high equity ratio of 81.74%, indicating a solid capital base. The debt-to-equity ratio is low at 0.04, reflecting minimal leverage and reduced financial risk. However, the return on equity remains negative, driven by sustained net losses, which undermines the overall financial health.

Cash Flow

The cash flow statement indicates significant operational challenges, with zero operating and free cash flow in the latest period. The absence of positive cash flows highlights ongoing operational inefficiencies. The company has shown improvements in reducing free cash flow deficits over the years, but cash flow management remains an area of concern.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	367.53M	361.56M	336.21M	251.03M	200.81M	103.93M
Gross Profit	253.91M	251.21M	229.93M	162.13M	118.70M	45.38M
EBITDA	-87.81M	-113.32M	-386.05M	-347.91M	-173.99M	-227.43M
Net Income	4.85M	-49.45M	-471.53M	-454.39M	-183.26M	-398.09M
Balance Sheet
Total Assets	2.67B	2.68B	2.58B	3.00B	3.36B	1.11B
Cash, Cash Equivalents and Short-Term Investments	1.32B	1.36B	1.07B	2.08B	2.42B	612.47M
Total Debt	279.62M	76.86M	70.48M	95.47M	125.64M	15.83M
Total Liabilities	450.55M	454.07M	242.25M	247.55M	265.52M	1.46B
Stockholders Equity	2.18B	2.19B	2.33B	2.75B	3.10B	-345.18M
Cash Flow
Free Cash Flow	-179.62M	-270.06M	-237.50M	-231.60M	-269.94M	-167.97M
Operating Cash Flow	-26.82M	-111.67M	-206.99M	-182.53M	-161.50M	-109.75M
Investing Cash Flow	-668.17M	-798.50M	-596.06M	-179.78M	-437.48M	-56.42M
Financing Cash Flow	-2.75M	-56.31M	-25.61M	-136.42M	2.23B	676.42M

MicroPort CardioFlow Medtech Corp. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.11
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2160, the sentiment is Negative. The current price of 1.11 is below the 20-day moving average (MA) of 1.16, below the 50-day MA of 1.21, and below the 200-day MA of 1.13, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 40.87 is Neutral, neither overbought nor oversold. The STOCH value of 36.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2160.

MicroPort CardioFlow Medtech Corp. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1789	69 Neutral	HK$6.13B	19.13	11.24%	1.32%	25.18%	55.79%
1858	55 Neutral	HK$9.02B	20.99	8.69%	1.87%	14.56%	61.60%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2160	43 Neutral	HK$2.68B	504.55	0.22%	―	-4.38%	―
2500	41 Neutral	HK$1.01B	-1.44	-26.80%	―	-8.56%	-14.84%
2393	40 Underperform	HK$244.61M	-1.39	-29.79%	―	6.10%	-115.12%
9996	39 Underperform	€3.90B	-15.90	-11.20%	―	29.25%	9.02%

MicroPort CardioFlow Medtech Corp. Corporate Events

MicroPort CardioFlow Clarifies EGM Voting Deadline

MicroPort CardioFlow Medtech Corporation has issued a supplemental announcement to clarify the deadline for lodging share transfers to qualify for voting rights at the upcoming Extraordinary General Meeting (EGM). The corrected deadline is now set for 4:30 p.m. on Tuesday, December 9, 2025, instead of the previously stated date. This clarification ensures stakeholders are accurately informed about the voting process, maintaining transparency and trust in the company’s governance.

MicroPort CardioFlow Medtech Announces Merger Plans

MicroPort CardioFlow Medtech Corp. has announced an extraordinary general meeting to discuss a proposed merger with MicroPort Cardiac Rhythm Management Limited. The merger involves issuing new shares to the target company’s shareholders, which could significantly impact the company’s market position and shareholder value.

MicroPort CardioFlow Expands with Major Acquisition in Cardiac Rhythm Management

MicroPort CardioFlow Medtech Corp. announced a significant acquisition involving the merger with a target company specializing in cardiac rhythm management. The transaction, valued at $680 million, will see the target company become an indirect subsidiary of MicroPort, enhancing its product platform and global market reach. This strategic move is expected to create synergies that will strengthen MicroPort’s position in the heart disease market by expanding its product pipeline and distribution capabilities.